ArcticZymes Technologies (AZT) Q3 2026 earnings summary

Executive summary

• Q3 sales revenue rose 15% YoY to NOK 32.9m, or 24% at constant currency, led by 44% Biomanufacturing growth.

• 9M sales rose 23% to NOK 96.6m; EBITDA increased to NOK 12.1m from NOK 3.7m, and EBIT turned profitable at NOK 5.3m.

Financial highlights

• Q3 sales revenue was NOK 32.9m; total revenue was NOK 33.1m.

• Q3 EBITDA was NOK 3.1m versus NOK 3.5m; EBIT was NOK 0.9m versus NOK 1.3m, and net profit was NOK 1.4m versus NOK 2.8m.

• 9M total revenue was NOK 102.1m; net profit rose to NOK 7.2m from NOK 3.0m.

• At constant currency, estimated EBITDA was NOK 5.5m in Q3 and NOK 19.8m in 9M.

Outlook and guidance

• 2026–2028 ambition remains sustainable double-digit growth, market outperformance, EBITDA margin expansion, stronger cash generation, and selective value-accretive investment.

• Priorities include scaling commercial execution, deeper workflow penetration, advancing R&D, expanding SAN GMP and NGS/metagenomics exposure, and establishing RNA as a growth pillar.

• RNA revenue is expected to build as early-access customers adopt and scale the products; the portfolio is planned to expand over coming years.